Skip to main content

Federal Court Rejects ArcherDx Motion Against Natera in Patent Infringement Lawsuit

NEW YORK – Natera said on Monday that its patent infringement lawsuit against ArcherDx is moving ahead after the US District Court for the District of Delaware rejected a motion by ArcherDx to dismiss the action.

Last month, the court also ordered the two separate lawsuits that Natera had filed against ArcherDx, which was just acquired by Invitae for around $1.4 billion, to be consolidated into one.

Natera filed its first complaint against ArcherDx in January, alleging that the Boulder, Colorado-based company infringes its US Patent No. 10,538,814, titled "Methods for simultaneous amplification of target loci." In April, it expanded that suit to include three additional patents.

In August, Natera filed a separate action against ArcherDx, claiming infringement of its US Patent No. 10,731,220, also titled "Methods for simultaneous amplification of target loci." Later that month, ArcherDx filed counterclaims to that complaint. On Sept. 25, the judge in that case ordered that the two actions be consolidated under the earlier case.

According to Natera, the court has now rejected "all of ArcherDx's challenges in Natera's ongoing patent infringement action," upholding the validity of Natera's asserted patents and rejecting ArcherDx's request to remove some of its cancer monitoring products from the case.

"Natera will continue to prosecute its five-patent infringement case against ArcherDx and will vigorously protect its innovative technology and broad IP claims in the fields of cancer monitoring and multiplex PCR," the company said in a statement.

An ArcherDx spokesperson said the company is not commenting on active, ongoing litigation.